Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Gross Profit (2024 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Gross Profit for 2 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 324.62% year-over-year to $1.4 million, compared with a TTM value of $28.4 million through Sep 2025, up 4414.33%, and an annual FY2024 reading of $1.8 million, changed N/A over the prior year.
  • Gross Profit was $1.4 million for Q3 2025 at X4 Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $24.1 million in Q1 2025 and bottomed at $295000.0 in Q2 2024.